Egenesis has raised $554M across 3 funding rounds, plus 2 undated rounds. The company is valued at $350M (post-money).
Lux Capital backs eGenesis alongside other investors. The company raised $191 million in a Series D round in 2024 to advance its lead kidney transplant program, EGEN-2784, toward pivotal trials.
3 funding rounds, the latest highlighted.
Egenesis was founded in 2015, United States.
No date is disclosed for this round.
A primary round — the company sells new shares to investors it selects. $100M raised, led by Fresenius Medical Care Ventures.
A primary round — the company sells new shares to investors it selects. $125M raised.
No filing has been made.
3 dated rounds, newest first.
Lux CapitalLEAD
Fresenius Medical Care VenturesLEAD
ARCH Ventures
Khosla Ventures
Farallon CapitalAAlta PartnersLLeaps by BayerDDaVitaEEisai InnovationNNATCO PharmaceuticalsPParkwood CorporationThe closest biotechnology / healthcare peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
No. Egenesis is a private company; its shares do not trade on a public exchange.
The last valuation is $350M.
Lead investors for each round are in the funding timeline.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
